SMS Pharmaceuticals Limited (SMSPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹39.1B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +18.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹214.42 – ₹438.30 · fair‑value band ₹132.04 – ₹264.00 · the ₹421.45 price screens above the ₹188.63 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SMS Pharmaceuticals Limited (SMSPHARMA) currently trades at ₹421.45, while our model-based Fair Value estimate is ₹188.63 — implying the stock looks roughly 55.2% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, SMS Pharmaceuticals Limited generated revenue of ₹8.9B at a net margin of 11.5%. Revenue declined 4.1% year over year. It earns a return on equity of 14.3%. Net debt stands at ₹3.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
SMS Pharmaceuticals Limited reported revenue of ₹8.9B in FY2026 versus ₹5.2B in FY2022, a compound +14.6%/yr. Reported net income was ₹1.0B in FY2026, compounding +13.2%/yr from FY2022.
Is SMSPHARMA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SMS Pharmaceuticals Limited (SMSPHARMA) undervalued?
What is the fair value of SMSPHARMA?
What is the quality score of SMSPHARMA?
What is the revenue of SMS Pharmaceuticals Limited (SMSPHARMA)?
What is the net profit margin of SMSPHARMA?
Does SMS Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.